Comparing Asiaticoside to Calcium Hydroxide and Ledermix as Intracanal Medications for Treating Infection and Inflammation in Teeth with Apical Periodontitis

What this Trial Is About

Researchers are evaluating the effectiveness of Asiaticoside as an intracanal medication compared to commonly used treatments like calcium hydroxide and Ledermix in teeth affected by apical periodontitis. The study focuses on measuring bacterial levels and inflammatory cytokines in root canals and surrounding tissues to better understand how these medications impact infection and inflammation in this dental condition. This investigation is conducted as a Phase 2 and Phase 3 clinical trial with a randomized and double-blind design. Participants will receive one of three intracanal medications Asiaticoside, calcium hydroxide, or Ledermix. These treatments will be applied inside the root canals of single-rooted teeth diagnosed with pulp necrosis and apical periodontitis. The study compares these medications directly to assess their effects on bacteria and inflammatory markers over time. During the study, researchers will count bacterial colonies using microbiology culturing techniques up to seven months after treatment. They will also measure inflammatory cytokines such as tumor necrosis factor, interleukin-1 beta, and prostaglandin E2 using ELISA tests for up to 25 weeks. Participants will be monitored carefully to track changes in infection levels and inflammation, contributing to understanding the treatments impact. The total participation period spans several months with detailed laboratory evaluations.

Effectiveness of Asiaticoside as Intracanal Medication on Infectious/Inflammatory Contents in Teeth With Apical Periodontitis